Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

Original reporting
Published Oct 21, 2026, 5:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra (IART) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings release provides fresh numbers and a guidance downgrade, creating immediate trading relevance.

02

Market read

New earnings and guidance data make the story highly relevant for traders holding or considering IART.

03

What to watch

Potential upside from upcoming SurgiMend launch and strong neurosurgery momentum may offset near‑term weakness.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Integra LifeSciences disclosed its Q3 2026 results, highlighting flood disruption at its Cincinnati site and a revised full‑year outlook.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra reported Q3 2026 earnings with $0.59 EPS, $411.2M revenue and cut full-year revenue guidance by $30M due to flood impact.

Expected impact

likely pressure as investors price in lower revenue outlook

Evidence & confidence

Earnings beat EPS but revenue guidance cut and operational disruption are material negative catalysts.

Market effects

Tissue reconstruction and neurosurgery segments may see mixed sentiment; peers could face similar flood‑related risks.

U.S. healthcare equipment sector may see modest pullback on guidance cuts.

Limited to U.S. med‑tech investors; no broader macro effect.

Counterpoint

Despite guidance cut, cash flow strength and leverage reduction could support a short‑term bounce.

Key entities

  • Integra LifeSciences

    Medical device manufacturer reporting Q3 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.